GET THE APP

KIT Testing and Survival in Malignant Melanoma Patients | Abstract

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

KIT Testing and Survival in Malignant Melanoma Patients

Author(s): Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi

Abstract

Malignant melanoma is the most common lethal cutaneous malignancy. It arises from melanocytes that originate from neural crest [1]. Alterations in KIT proto-oncogene define a unique molecular subset in malignant melanoma. Mutations and amplification of KIT are observed in 3% of all melanomas and are more common in melanoma cases arising from mucosal, acral or chronically sun-damaged surfaces [2]. The clinical application of KIT inhibition in melanomas driven by KIT alterations has been reported in patients treated with agents such as imatinib, dasatinib, sorafenib and sunitinib [3]. The study consisted of 11 of cases of malignant melanoma that had referred to the oncology clinic in Kermanshah, Iran. There were 5 male and 6 female patients with mean age ± SD of 57.2±18.94 years (range, 18-78 years). Of 11 patients, 5 (45.5%) showed KIT positivity. Two patients had lymph node involvement and all patients had BRAF of wild-type. The 5-year survival rate for all patients was 54.5% and mean survival was 37.5 months (Figure 1A). The 5-year survival rate of the patients with KIT positivity and KIT negativity was 60% and 50%, respectively, mean survival was 42.2 and 33.6 months, respectively (Figure 1B).

Share this article

cappadocia tours
cappadocia hotels
cappadocia balloon flights

paper.io

agar io

wormax io